Burden and clinical features of atypical hemolytic uremic syndrome in Egyptian hospitals

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

This project looks at medical records to describe how aHUS affects patients treated in participating Egyptian hospitals from 2010 to 2023.

Quick facts

• Study type: Observational
• Enrollment: 200 (estimated)
• Sex: All
• Sponsor: AstraZeneca (Industry-sponsored)
• Locations: 8 sites (Al Mansurah and 7 other locations)
• Trial ID: NCT07218536 on ClinicalTrials.gov

What this trial studies

This is a multicenter retrospective cohort review of medical records from patients diagnosed with thrombotic microangiopathy (TMA) between January 1, 2010 and December 31, 2023 at several Egyptian hospitals. Records will be screened to identify patients with a diagnosis of atypical hemolytic uremic syndrome (aHUS) and to extract clinical, laboratory, genetic, treatment, and outcome data. The analysis will summarize disease burden, organ involvement, genetic findings when available, rates of dialysis, progression to end-stage renal disease, and mortality. No experimental interventions are given; the project is observational and descriptive, sponsored by AstraZeneca.

Who should consider this trial

Good fit: Patients of any age (one month or older) who were diagnosed with TMA and treated at the participating Egyptian hospitals between January 1, 2010 and December 31, 2023 are eligible for record inclusion.

Not a fit: Patients treated outside the participating hospitals or outside the 2010–2023 date range, or those without a confirmed aHUS diagnosis, are unlikely to benefit directly from this analysis.

Why it matters

Potential benefit: If successful, the findings could improve understanding of how aHUS presents and progresses in Egypt, helping clinicians and health planners improve diagnosis, monitoring, and management.

How similar studies have performed: Similar retrospective cohorts in other countries have characterized aHUS epidemiology and outcomes, so the approach is established though Egyptian-specific data are limited.

Eligibility criteria

Inclusion Criteria:

* Male or female patients aged one month or older who have been diagnosed with TMA between 01-Jan-2010 and 31-Dec-2023.

Exclusion Criteria:

* None. All records of patients with TMA will be screened for aHUS diagnosis.

Where this trial is running

Al Mansurah and 7 other locations

• Research Site — Al Mansurah, Egypt (Not_yet_recruiting)
• Research Site — Alexandria, Egypt (Recruiting)
• Research Site — Asyut, Egypt (Recruiting)
• Research Site — Cairo, Egypt (Recruiting)
• Research Site — New Cairo, Egypt (Not_yet_recruiting)
• Research Site — New Cairo, Egypt (Recruiting)
• Research Site — Tanta, Egypt (Recruiting)
• Research Site — Zagazig, Egypt (Recruiting)

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center

Conditions Atypical Hemolytic Uremic Syndrome